Erick F. Sandoval

Farmacéutico 🏀 🤿 🏝 🎼

[Erick F. Sandoval @ericknando23]

https://t.co/6wECxXyOqw

[Boehringer Ingelheim @boehringerus]

#NEWS: Detect the SOS, a public health mission urging adults with high blood pressure or type 2 diabetes to prioritize uACR screening to help uncover hidden kidney & heart risk, launches Feb. 8 during the Big Game. Learn more: https://t.co/115r6L6r4X

[PharmaShots | Iluminate.Innovate.Inspire @Pharmashot]

Boehringer Ingelheim Secures the US FDA’s Approval for Jascayd (Nerandomilast) to Treat Idiopathic Pulmonary Fibrosis

#bi1015550 #boehringeringelheim #jascayd #usfda #approval #fibroneeripf #piii #trial2 #pii #pde4binhibitor #regulatory

https://t.co/seWfRdh7oX

[FiercePharma @FiercePharma]

Boehringer's Jascayd is the first new drug to break into the idiopathic pulmonary fibrosis field in more than a decade. https://t.co/0EuPevcQVf

[AJMC @AJMC_Journal]

🚨 FDA grants accelerated approval to #zongertinib (Hernexeos; Boehringer Ingelheim) for adults with unresectable/metastatic nonsquamous #NSCLC w/ HER2 TKD–activating mutations after prior systemic therapy. Read more: https://t.co/PpdCTlzjcM

[Erick F. Sandoval @ericknando23]

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes | New England Journal of Medicine https://t.co/pqIyWj9dLp

[Boehringer Ingelheim @BoehringerSA]

En el Día Mundial del ACV recordamos cuáles los síntomas de un accidente cerebrovascular, para poder actuar a tiempo y reducir el riesgo de daño cerebral:
•Desviación de la boca
•Falta de fuerza en un brazo
•Dificultades para hablar
•Hormigueo en los brazos

[Boehringer Ingelheim @Boehringer]

#NEWS: Our Ph II full data results for adults with #MASH and liver fibrosis F1, F2, & F3 showed the trial met all key secondary endpoints and its primary endpoint. The data were presented today at @EASLnews.

#LifeForward #EASLCongress

Read more: https://t.co/ZSKsot9j93

[Papa Francisco – ARCHIVO @Pontifex266_es]

El verdadero progreso de las naciones no se mide por la riqueza económica y mucho menos por los que invierten en la ilusoria potencia de los armamentos, sino por la capacidad de hacerse cargo de la salud, la educación y el crecimiento integral de la gente. #Mongolia

[Medscape @Medscape]

The FDA has approved empagliflozin and empagliflozin combined with metformin for the treatment of type 2 diabetes in children aged 10 years and older. https://t.co/ntVMYr6wMB

[Boehringer Ingelheim @Boehringer]

#NEWS: Together with @EliLillyandCo we are delighted to announce that EMA's #CHMP granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of #ChronicKidneyDisease (CKD). Read more about this important step towards approval: https://t.co/Zcm1Nz1uH#NEWS: Together with @EliLillyandCo we are delighted to announce that EMA's #CHMP granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of #ChronicKidneyDisease (CKD). Read more about this important step towards approval: https://t.co/Zcm1Nz1uH#NEWS: Together with @EliLillyandCo we are delighted to announce that EMA's #CHMP granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of #ChronicKidneyDisease (CKD). Read more about this important step towards approval: https://t.co/Zcm1Nz1uH#NEWS: Together with @EliLillyandCo we are delighted to announce that EMA's #CHMP granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of #ChronicKidneyDisease (CKD). Read more about this important step towards approval: https://t.co/Zcm1Nz1uHx

[Erick F. Sandoval @ericknando23]

@Mr_JAFF 8====>

[Alfonso Valle @ValleAlfonso]

Todo llega🇪🇸👇
#Empagliflocina desde el 01.02.23👇

financiado para el tratamiento en adultos de la #IC crónica sintomática, independientemente de la FEVI

📥 https://t.co/rLUiQrPaoP

[NEJM @NEJM]

In this trial involving patients with chronic kidney disease, empagliflozin resulted in a lower risk of disease progression or death from cardiovascular causes than placebo. #KidneyWk https://t.co/HFgzPgrRFx

[Cristobal Morales @CristobMorales]

https://t.co/Jq9jcdzdZQ Empagliflozin in Patients with Chronic Kidney Disease #EMPAKIDNEY Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or CV death

[CardioTeca @cardioteca]

📢❤️ EMMY trial: #Empagliflozina en pacientes con Infarto de Miocardio

👩🏻‍⚕️ Comentario Dra. @Carol_O_C

✅ https://t.co/yK5JnDUYjE

#ctkempa #insuficienciacardiaca

[Henry Han @HanCardiomd]

#Empagliflozin therapy was associated with an approximate 40% reduced risk of urinary tract stone events in T2DM

A Potential New Role for #SGLT2i?

https://t.co/4QxHMvxiL7 #CKD #RenalStone #HeartFailure
@kidney_boy @NephroP @JavedButler1 @gcfmd @SJGreene_md @DrRyanPDaly

[Henry Han @HanCardiomd]

#Empagliflozin in #AMI: the #EMMY trial

Empagliflozin initiated shortly after an AMI improves #NTproBNP, as well as structural and functional #EchoFirst parameters ( LVEF, E/e’, LVESV and LVEDV) without significant safety concerns

https://t.co/hQ5jz3uOCH @escardio #HeartFailure

[CVR Tomasz Guzik @CVR_TomaszGuzik]

Congratulations to the winner of the #CardiovascularResearch top cited paper published in 2021, showing #Empagliflozin reduces #inflammatory & oxidative stress in #HFpEF & leads to less pathological #cardiomyocyte stiffness

Read the paper: https://t.co/4PQyU0aZ5a

#ESCCongress